Nanohale AG (ETR:FYB)

BRIEF

published on 03/24/2025 at 06:35, 10 months 6 days ago

Formycon AG Announces Conference Call and Event Participation

Financial Results Conference Call Formycon Investor Events International Conferences
PRESS RELEASE

published on 03/24/2025 at 06:30, 10 months 6 days ago

Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Formycon announces conference call for fiscal year 2024 results and participation in investor conferences in Q2 2025

Conference Call Investor Conferences Financial Year 2024 Biosimilars Formycon
BRIEF

published on 03/03/2025 at 14:05, 10 months 26 days ago

FYB202/Otulfi® Biosimilar Launched in the U.S. and EU

Healthcare Access Ustekinumab Biosimilar Launch Market Availability Cost-effective Therapy
PRESS RELEASE

published on 03/03/2025 at 14:00, 10 months 26 days ago

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, officially launched in the United States and European Union, offering comparable efficacy and safety. Formycon AG and Fresenius ensure successful market access

Formycon AG Launch Biosimilar Stelara Otulfi
BRIEF

published on 02/25/2025 at 06:35, 11 months 5 days ago

Formycon's FYB203 Receives UK Regulatory Approval

UK Regulatory Biosimilar Approval Formycon FYB203 Ophthalmic Treatment Teva Partnership
PRESS RELEASE

published on 02/25/2025 at 06:30, 11 months 5 days ago

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA

Regulatory Approval UK Biosimilar Formycon AHZANTIVE
BRIEF

published on 02/24/2025 at 11:31, 11 months 6 days ago

Formycon AG: Price Target Adjusted Amid Market Pressures

Buy Recommendation Formycon AG Price Pressure Biosimilar Market Investment Reduction
PRESS RELEASE

published on 02/24/2025 at 11:26, 11 months 6 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 11 months 10 days ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
PRESS RELEASE

published on 02/20/2025 at 06:30, 11 months 10 days ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab

Published on 01/30/2026 at 08:35, 4 hours 28 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 5 hours 3 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 10 hours 48 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 13 hours 3 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 14 hours 3 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE

Published on 01/30/2026 at 12:00, 1 hour 3 minutes ago

HSBC UK and Sage simplify tax reporting for small businesses ahead of Making Tax Digital
Published on 01/30/2026 at 11:54, 1 hour 9 minutes ago

EQS-Adhoc: YOC AG: PRELIMINARY FIGURES FOR THE 2025 FINANCIAL YEAR
Published on 01/30/2026 at 10:30, 2 hours 33 minutes ago

ASTA ENERGY SOLUTIONS AG SUCCESSFULLY COMPLETES IPO
Published on 01/30/2026 at 10:00, 3 hours 3 minutes ago

Appointment of Managing Director of Tradegate BSX
Published on 01/30/2026 at 09:00, 4 hours 2 minutes ago

Original-Research: 123fahrschule SE (von NuWays AG): BUY

View all EQS

Published on 01/30/2026 at 08:00, 5 hours 3 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 19 hours 3 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 19 hours 18 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 19 hours 18 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 19 hours 23 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News